Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
January 31, 2007

Axxam and Boehringer Ink Two Drug Research Agreements

  • Axxam signed two drug research collaboration agreements with Boehringer Ingelheim. The first collaboration agreement aims to identify and validate therapeutic targets with subsequent assay development, high-throughput screening (HTS), and lead optimizations.

    The second agreement covers the transfer of protein material and a corresponding specific functional assay for HTS to Boehringer Ingelheim.

    Axxam will receive fees as the collaboration progresses and milestone payments for successful exploitation of results through development stages.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.